SEP360-108
Total Payments
$362,572
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $362,572 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $362,572 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| SEP360-108 | Sunovion Pharmaceuticals Inc. | $362,572 | 0 |
Top Doctors Receiving Payments for SEP360-108
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Boston, MA | $362,572 | 2 |
Ad
Manufacturing Companies
- Sunovion Pharmaceuticals Inc. $362,572
Product Information
- Type Drug
- Total Payments $362,572
- Total Doctors 0
- Transactions 2
About SEP360-108
SEP360-108 is a drug associated with $362,572 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is Sunovion Pharmaceuticals Inc..
Payment data is available from 2017 to 2017. In 2017, $362,572 was paid across 2 transactions to 0 doctors.
The most common payment nature for SEP360-108 is "Unspecified" ($362,572, 100.0% of total).
SEP360-108 is associated with 1 research study, including "SEP360-108" ($362,572).